Literature DB >> 14747283

Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

Li-Jun Ma1, Su-Li Mao, Kevin L Taylor, Talerngsak Kanjanabuch, YouFei Guan, YaHua Zhang, Nancy J Brown, Larry L Swift, Owen P McGuinness, David H Wasserman, Douglas E Vaughan, Agnes B Fogo.   

Abstract

Increased plasminogen activator inhibitor 1 (PAI-1) has been linked to not only thrombosis and fibrosis but also to obesity and insulin resistance. Increased PAI-1 levels have been presumed to be consequent to obesity. We investigated the interrelationships of PAI-1, obesity, and insulin resistance in a high-fat/high-carbohydrate (HF) diet-induced obesity model in wild-type (WT) and PAI-1-deficient mice (PAI-1(-/-)). Obesity and insulin resistance developing in WT mice on an HF diet were completely prevented in mice lacking PAI-1. PAI-1(-/-) mice on an HF diet had increased resting metabolic rates and total energy expenditure compared with WT mice, along with a marked increase in uncoupling protein 3 mRNA expression in skeletal muscle, likely mechanisms contributing to the prevention of obesity. In addition, insulin sensitivity was enhanced significantly in PAI-1(-/-) mice on an HF diet, as shown by euglycemic-hyperinsulinemic clamp studies. Peroxisome proliferator-activated receptor (PPAR)-gamma and adiponectin mRNA, key control molecules in lipid metabolism and insulin sensitivity, were maintained in response to an HF diet in white adipose tissue in PAI-1(-/-) mice, contrasting with downregulation in WT mice. This maintenance of PPAR-gamma and adiponectin may also contribute to the observed maintenance of body weight and insulin sensitivity in PAI-1(-/-) mice. Treatment in WT mice on an HF diet with the angiotensin type 1 receptor antagonist to downregulate PAI-1 indeed inhibited PAI-1 increases and ameliorated diet-induced obesity, hyperglycemia, and hyperinsulinemia. PAI-1 deficiency also enhanced basal and insulin-stimulated glucose uptake in adipose cells in vitro. Our data suggest that PAI-1 may not merely increase in response to obesity and insulin resistance, but may have a direct causal role in obesity and insulin resistance. Inhibition of PAI-1 might provide a novel anti-obesity and anti-insulin resistance treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747283     DOI: 10.2337/diabetes.53.2.336

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  108 in total

1.  Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.

Authors:  Ashley A Reinke; Shih-Hon Li; Mark Warnock; Maxim E Shaydakov; Naga Sandhya Guntaka; Enming J Su; Jose A Diaz; Cory D Emal; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2018-12-03       Impact factor: 5.157

2.  Apoptosis of hematopoietic progenitor-derived adipose tissue-resident macrophages contributes to insulin resistance after myocardial infarction.

Authors:  Sathish Babu Vasamsetti; Emilie Coppin; Xinyi Zhang; Jonathan Florentin; Sasha Koul; Matthias Götberg; Andrew S Clugston; Floyd Thoma; John Sembrat; Grant C Bullock; Dennis Kostka; Claudette M St Croix; Ansuman Chattopadhyay; Mauricio Rojas; Suresh R Mulukutla; Partha Dutta
Journal:  Sci Transl Med       Date:  2020-07-22       Impact factor: 17.956

Review 3.  An immune origin of type 2 diabetes?

Authors:  H Kolb; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

4.  PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells.

Authors:  Caiyan Zhao; Wei Chen; Liu Yang; Lihong Chen; Stephen A Stimpson; Anna Mae Diehl
Journal:  Biochem Biophys Res Commun       Date:  2006-09-22       Impact factor: 3.575

Review 5.  Genetic Effects on the Correlation Structure of CVD Risk Factors: Exome-Wide Data From a Ghanaian Population.

Authors:  Nuri Kodaman; Rafal S Sobota; Folkert W Asselbergs; Matthew T Oetjens; Jason H Moore; Nancy J Brown; Melinda C Aldrich; Scott M Williams
Journal:  Glob Heart       Date:  2017-04-10

Review 6.  Adipocyte-derived hormones, cytokines, and mediators.

Authors:  Cristina M Rondinone
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

7.  Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk.

Authors:  Luqian Zhao; Ping Huang
Journal:  Int J Clin Exp Med       Date:  2013-09-01

Review 8.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

Review 9.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

10.  Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis.

Authors:  Mark M Smits; Pier Woudstra; Kristina M Utzschneider; Jenny Tong; Fernando Gerchman; Mirjam Faulenbach; Darcy B Carr; Kathryn Aston-Mourney; Alan Chait; Robert H Knopp; James B Meigs; Edward J Boyko; Steven E Kahn
Journal:  Ann Epidemiol       Date:  2013-03-25       Impact factor: 3.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.